Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression

British Journal of Dermatology

Volumn 156, Issue 4, 2007, Pages 653-658

  Kurschat, P ^a   Eming, S ^a   Nashan, D ^b   Krieg, T ^a   Mauch, C ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiogenesis; Endostatin; Fibroblast growth factor; Melanoma progression; Tumour marker; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; ENDOSTATIN; PROTEIN S100B; TUMOR MARKER; VASCULOTROPIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; DISEASE PROGRESSION; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MELANOMA; MIDDLE AGED; NERVE GROWTH FACTORS; S100 PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33947355893     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07724.x     Document Type: Article

References (21)

1. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14:280-90.
2. Balch CM, Buzaid AC, Atkins MB et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88:1484-91.
3. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48.
4. Hauschild A, Engel G, Brenner W et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999; 56:338-44.
5. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3:401-10.
6. Huang Z, Bao SD. Roles of main pro- and anti-angiogenic factors in tumor angiogenesis. World J Gastroenterol 2004; 10:463-70.
7. Zatterstrom UK, Felbor U, Fukai N, Olsen BR. Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct 2000; 25:97-101.
8. Feldman AL, Tamarkin L, Paciotti GF et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 2000; 6:4628-34.
9. Suzuki M, Iizasa T, Ko E et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002; 35:29-34.
10. Kuroi K, Toi M. Circulating angiogenesis regulators in cancer patients. Int J Biol Markers 2001; 16:5-26.
11. Szabo S, Sandor Z. The diagnostic and prognostic value of tumor angiogenesis. Eur J Surg 1998: 582 (Suppl.):99-103.
12. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19:577-83.
13. Wen W, Moses MA, Wiederschain D et al. The generation of endostatin is mediated by elastase. Cancer Res 1999; 59:6052-6.
14. Ferreras M, Felbor U, Lenhard T et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000; 486:247-51.
15. Dunst J, Becker A, Lautenschlager C et al. Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol 2002; 178:436-41.
16. Asano M, Kaneoka K, Nomura T et al. Increase in serum vascular endothelial growth factor levels during altitude training. Acta Physiol Scan 1998; 162:455-9.
17. Kikuchi K, Kubo M, Kadano T et al. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998; 139:1049-51.
18. Seko Y, Fukuda S, Nagai R. Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy. Clin Sci 2004; 106:439-42.
19. McIlhenny C, George WD, Doughty JC. A comparison of serum and plasma levels of vascular endothelial growth factor during the menstrual cycle in healthy female volunteers. Br J Cancer 2002; 86:1786-9.
20. Benoy I, Vermeulen P, Wuyts H, Dirix L. Vascular endothelial growth factor (VEGF) serum concentrations change according to the phase of the menstrual cycle. Eur J Cancer 1998; 34:1298-9.
21. Dirix LY, Vermeulen PB, Pawinski A et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997; 76:238-43.